Structure Therapeutics Inc. has announced the initiation of a Phase 1 clinical study for its lead drug candidate, ACCG-2671, designed to treat obesity. This first-in-human trial begins on December 17, 2025, in San Francisco, marking a significant milestone for the clinical-stage biopharmaceutical company. The study aims to evaluate the safety and efficacy of ACCG-2671, an oral small molecule amylin receptor agonist, which leverages the metabolic benefits associated with amylin biology.
The development of ACCG-2671 comes from Structure Therapeutics’ advanced structure-based drug discovery platform. This innovative approach allows for the creation of a once-daily oral medication that could enhance patient accessibility and scalability in obesity treatment. The drug has shown promising preclinical results, indicating robust weight loss both as a standalone treatment and in combination with other therapies.
Dr. Xichen Lin, Chief Scientific Officer of Structure Therapeutics, highlighted the potential of amylin-based therapies in transforming the obesity treatment landscape. He stated, “We believe amylin-based therapies are poised to become an important next-generation component of the treatment landscape for obesity and related conditions.”
ACCG-2671 has demonstrated potent target engagement in preclinical studies, showing significant weight reduction. The data suggest that when administered alone, and especially in conjunction with a glucagon-like-peptide receptor agonist (GLP-1 RA), the drug could enhance weight loss outcomes. Furthermore, the safety profile of ACCG-2671 appears favorable, with pharmacokinetics that support once-daily dosing.
This clinical study represents a critical step in the journey of ACCG-2671 toward potentially becoming a leading treatment option for obesity. As obesity rates continue to rise globally, the need for effective and accessible treatment options has never been greater. Structure Therapeutics aims to position ACCG-2671 as a key player in obesity management, both as a standalone therapy and in synergy with existing weight loss medications.
The company’s commitment to advancing innovative therapies underscores the potential for significant impacts on public health and quality of life. With the clinical trial underway, stakeholders in the biopharmaceutical industry and patients alike will be closely monitoring the progress of ACCG-2671 and its implications for obesity treatment strategies.
